This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Recently, the European Medicines Agency (EMA) took the lead in pushing for processimprovements using technologies already established in other manufacturing sectors. Yet in 2021, 100 nanomedicines had been marketed. Nanoparticle HIV vaccine shows potential in trial Nanomedicines generally require aseptic processing.
These innovative technologies include highly automated, fully digitalised process analytics technologies (PAT) , as well as automated and robotic testing technologies to confirm product quality. The complex and intricate processes involved in upstream and downstream manufacturing are highly refined, he notes.
Following approval of an initial marketing application, postapproval changes are needed to ensure adequate supply, mitigate supply risk, expand patient market access, optimize manufacturing processes, improve analytical methods, and comply with new regulatory expectations. Journal of Pharmaceutical Sciences (2021). 2021.09.046.
Towards Next Generation Antisense Oligonucleotides: Mesylphosphoramidate Modification Improves Therapeutic Index and Duration of Effect of Gapmer Antisense Oligonucleotides.” 16 (20 September 2021): 9026–41. “Oligonucleotide Therapeutics: From Discovery and Development to Patentability.” Pharmaceutics 14, no. 2 (February 2022): 260.
1 (2021):48. 6540 (2021):341–42. Pharmaceutical Processing World. 1 (2021):7200. 13 July 2021. Updated 22 July 2021. 2021, Washington, D.C.: Developing the Biofacility of the Future Based on Continuous Processing and Single-Use Technology.” 3 a b c Algorri, M., 3 (2022):593–607. October 2022.
linear) design process is central to successfully attaining such comprehensive sustainability goals and project needs (see Figure 1). 14–25 (November–December 2021). 25 February 2021. BioProcess International 8 December 2021 (November–December 2021) [link] 23 Bio-Process Systems Alliance. 14 Whitford, W.
In the long term, a collaboration between regulators and industry stakeholders to develop and implement harmonized guidelines for raw materials would help address flexibility challenges, prevent delays in implementing processimprovements, and ensure that both regulator and industry resources are devoted to the most critical issues.
Published 15 November 2021. The authors propose using Module 2.3 to effectively convey the control strategy and clearly identify the established conditions (ECs) or regulatory binding elements that “are considered necessary to assure product quality and therefore would require a regulatory submission if changed post approval.”
Published 15 November 2021. The authors propose using Module 2.3 to effectively convey the control strategy and clearly identify the established conditions (ECs) or regulatory binding elements that “are considered necessary to assure product quality and therefore would require a regulatory submission if changed post approval.”
In addition to delaying optimization of manufacturing and controls, these types of long delays for approvals discourage continuous processimprovements for approved products. Published 2021. IPRP Strategic Vision 2018–2021. WHO Expert Committee on Specifications for Pharmaceutical Preparations.” Accessed 14 June 2023.
According to GlobalData analysis, the number of clinical trials with a decentralised and virtual component increased by 50% between 2020 and 2021, and this trend is here to stay. The Covid-19 pandemic catalysed an enormous upswing in the adoption of innovations including telemedicine, wearables and remote patient monitoring.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content